EXTON, PA — ProRx Pharma expanded its manufacturing capacity, facility footprint, and distribution reach as part of a growth effort that includes entry into Oklahoma and Virginia and plans for additional states.
The company increased its facility size from about 3,400 square feet to approximately 17,000 square feet, adding clean rooms and specialized areas for sterile and non-sterile drug production.
The expansion supported a rise in production output, with monthly manufacturing volumes increasing since December and further gains expected in the coming months.
ProRx said it has invested in automation and quality systems, including an AI-based visual inspection system and additional aseptic filling equipment to support higher production levels.
The company is also adding a sterile hazardous drug clean room to support an expanded hormone replacement therapy portfolio.
Kurt Lunkwitz, chief operating officer at ProRx Pharma, said, “Our focus has been on building the infrastructure required to scale in a controlled way while maintaining quality and consistency across our operations.”
Workforce levels have roughly doubled in recent months, with the addition of pharmacists, quality control staff, operational personnel, and corporate support roles.
ProRx has also implemented training programs through the Parenteral Drug Association to support quality and compliance across its operations.
The company plans to introduce new injectable products, including testosterone and estradiol cypionate, in the coming months as part of its expanded portfolio.
Support the local news that supports Chester County. MyChesCo delivers reliable, fact-based reporting and essential community resources—free for everyone. If you value that, click here to become a patron today.